HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
5.72
+0.04 (0.70%)
At close: Aug 29, 2025, 4:00 PM
5.56
-0.16 (-2.80%)
After-hours: Aug 29, 2025, 7:58 PM EDT
HCW Biologics Revenue
HCW Biologics had revenue of $6.55K in the quarter ending June 30, 2025, a decrease of -98.94%. This brings the company's revenue in the last twelve months to $832.84K, down -78.77% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$832.84K
Revenue Growth
-78.77%
P/S Ratio
8.41
Revenue / Employee
$23,134
Employees
36
Market Cap
10.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
Dec 31, 2022 | 6.72M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 4.10M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
HCWB News
- 5 days ago - HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform - Benzinga
- 5 days ago - HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market - GlobeNewsWire
- 12 days ago - HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors - GlobeNewsWire
- 2 months ago - HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements - GlobeNewsWire
- 3 months ago - HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech - GlobeNewsWire
- 3 months ago - HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire